A Phase IB open-label, dose-escalation study of NUC‑1031 in combination with carboplatin for recurrent ovarian cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-4403 ◽

2021 ◽

pp. clincanres.4403.2020

Author(s):

Farasat Kazmi ◽

Shibani Nicum ◽

Rene L Roux ◽

Laura Spiers ◽

Chat Gnanaranjan ◽

...

Keyword(s):

Ovarian Cancer ◽

Dose Escalation ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Label Dose

Download Full-text

A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.05.001 ◽

2018 ◽

Vol 150 (1) ◽

pp. 23-30 ◽

Cited By ~ 25

Author(s):

Clemens B. Tempfer ◽

Urs Giger-Pabst ◽

Veronika Seebacher ◽

Miriam Petersen ◽

Askin Dogan ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Peritoneal Carcinomatosis ◽

Dose Escalation ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose

Download Full-text

A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.2103 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 2103-2103 ◽

Cited By ~ 4

Author(s):

J. Voortman ◽

E. F. Smit ◽

B. C. Kuenen ◽

H. M. Pinedo ◽

C. van Groeningen ◽

...

Keyword(s):

Dose Escalation ◽

Advanced Solid Tumors ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Label Dose ◽

Phase 1B ◽

First Line Treatment

Download Full-text

Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours

Annals of Oncology ◽

10.1093/annonc/mdz253.050 ◽

2019 ◽

Vol 30 ◽

pp. v500-v501

Author(s):

J. Strauss ◽

Y. Vugmeyster ◽

M. Sznol ◽

R.K. Pachynski ◽

K. Trang ◽

...

Keyword(s):

Dose Escalation ◽

Solid Tumours ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Label Dose

Download Full-text

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-019-05360-3 ◽

2019 ◽

Vol 178 (1) ◽

pp. 121-133

Author(s):

Vandana G. Abramson ◽

Mafalda Oliveira ◽

Andrés Cervantes ◽

Hans Wildiers ◽

Manish R. Patel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Dose Escalation ◽

Locally Advanced ◽

Metastatic Breast ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Label Dose

Download Full-text

PRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.039 ◽

2017 ◽

Vol 28 ◽

pp. v345 ◽

Cited By ~ 1

Author(s):

S.P. Blagden ◽

A. Sukumaran ◽

L. Spiers ◽

V.K. Woodcock ◽

A. Lipplaa ◽

...

Keyword(s):

Ovarian Cancer ◽

Dose Escalation ◽

Recurrent Ovarian Cancer ◽

Dose Escalation Study ◽

Phase Ib

Download Full-text

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Investigational New Drugs ◽

10.1007/s10637-020-00975-6 ◽

2020 ◽

Cited By ~ 1

Author(s):

Geoffrey I. Shapiro ◽

Patricia LoRusso ◽

Daniel C. Cho ◽

Luna Musib ◽

Yibing Yan ◽

...

Keyword(s):

Solid Tumors ◽

Dose Escalation ◽

Locally Advanced ◽

Pharmacokinetics And Pharmacodynamics ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Label Dose

Download Full-text

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

Journal of Translational Medicine ◽

10.1186/1479-5876-12-s1-p5 ◽

2014 ◽

Vol 12 (S1) ◽

Cited By ~ 15

Author(s):

Richard Kefford ◽

Ryan J Sullivan ◽

Wilson H Miller ◽

Elena M Elez ◽

Daniel Tan ◽

...

Keyword(s):

Solid Tumors ◽

Dose Escalation ◽

Braf Inhibitor ◽

Advanced Solid Tumors ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Preliminary Results ◽

Label Dose

Download Full-text

PD09-04: A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of the PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-pd09-04 ◽

2011 ◽

Author(s):

P Schöffski ◽

E De Benedictis ◽

S Gendreau ◽

L Gianni ◽

IE Krop ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Dose Escalation ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Label Dose ◽

Locally Recurrent

Download Full-text

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China

Case Medical Research ◽

10.31525/ct1-nct03998345 ◽

2019 ◽

Author(s):

Keyword(s):

Dose Escalation ◽

Phase 1 ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose

Download Full-text

Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: A 29-day, multicenter, open-Label, dose-escalation study

Clinical Therapeutics ◽

10.1016/j.clinthera.2006.10.005 ◽

2006 ◽

Vol 28 (10) ◽

pp. 1607-1618 ◽

Cited By ~ 20

Author(s):

Ronald A. Thisted ◽

Leslie Klaff ◽

Sherwyn L. Schwartz ◽

James P. Wymer ◽

Neil W. Culligan ◽

...

Keyword(s):

Peripheral Neuropathy ◽

Dose Escalation ◽

Diabetic Peripheral Neuropathy ◽

Adult Patients ◽

Open Label ◽

Dose Escalation Study ◽

Painful Diabetic Peripheral Neuropathy ◽

Label Dose

Download Full-text